Publications by authors named "Gavin Cull"

Claim this Profile
O
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
Ramón García-Sanz, Roger G Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen McCarthy, Gavin Cull

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and outcomes of post-transplant lymphoproliferative disorder in the Western Australian liver transplant population: a 24-year retrospective study.
Rohita Reji, Gavin Cull, Julie Crawford, Leon Adams, George Garas

Intern Med J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, Paolo Ghia, Ian W Flinn, Gavin Cull

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.
Elizabeth Hughes, Sue Latham, Bryone Kuss, Scott Grist, Rachel Hall, Gavin Cull

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.
Daniel Fasser, Katharine Lewis, Connull Leslie, Gavin Cull, Dejan Radeski

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
Diva Baggio, Eliza Chung, Cameron Wellard, Neil Waters, Tania Cushion, Gavin Cull

Intern Med J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Jacoline E C Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Gavin Cull

Neuro Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Gavin Cull

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Sun Loo, Andrew W Roberts, Natasha S Anstee, Glen A Kennedy, Simon He, Gavin Cull

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Mary A Anderson, Rory Bennett, Xavier Badoux, Giles Best, Nicole Chia, Gavin Cull

Intern Med J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.
Constantine Tam, Javier Munoz, Gavin Cull, Stephen Opat, Heather Allewelt

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic mastocytosis associated with two clonal haematological neoplasms.
Ashlyn Chee, Wendy N Erber, Gavin Cull

Pathology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Gavin Cull, Jan A Burger, Stephen Opat, David Gottlieb, Emma Verner

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Constantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, Judith Trotman, Stephen Opat, Gavin Cull

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
Matthijs van der Meulen, Linda Dirven, Esther J J Habets, Katerina Bakunina, Marion Smits, Gavin Cull

Neuro Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Constantine S Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz

Blood Adv· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
Matthijs van der Meulen, Alida A Postma, Marion Smits, Katerina Bakunina, Monique C Minnema, Gavin Cull

Neurooncol Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Gavin Cull

Blood Adv· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia.
Ashlyn Chee, Benjamin Wood, Genevieve Sadler, Gavin Cull

J Med Cases· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull

Blood· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull

Blood· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
Andrew J Sunderland, Raphael E Steiner, Musa Al Zahrani, Chelsea C Pinnix, Bouthaina Shbib Dabaja, Gavin Cull

Cancer Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marginal zone lymphoma causing accelerated progression of chronic kidney disease.
Amali Samarasinghe, Daniel Wong, Gavin Cull, Aron Chakera

BMJ Case Rep· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis